FFRangio System vs Impala

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
FFRangio System
by CathWorks (acquired by Medtronic)
VS
Impala
by AliveCor

AI Verdict

The FFRangio System and Impala are adjacent tools within cardiology AI, serving distinct purposes. FFRangio focuses on optimizing percutaneous coronary intervention (PCI) decisions by providing wire-free 3D FFR guidance for coronary artery disease in a cath lab setting. Impala, conversely, is a portable, AI-powered 12-Lead ECG device designed for rapid acquisition and detection of various cardiac conditions in a diagnostic context.

Choose FFRangio System if…

Choose the FFRangio System if you are an interventional cardiologist seeking to optimize percutaneous coronary intervention (PCI) decisions directly within the cath lab. This system provides real-time, wire-free, and drug-free 3D FFR guidance, allowing for comprehensive physiological assessment and confirmation of treatment efficacy without additional invasive steps. It is ideal for detailed multi-vessel analysis and lesion impact assessment during a procedure.

View FFRangio System →

Choose Impala if…

Choose Impala if you are a healthcare professional requiring rapid, portable, and AI-powered 12-Lead ECG acquisition for immediate cardiac assessment. This device is best suited for situations where quick detection of life-threatening cardiac conditions, such as heart attacks, is crucial, especially in emergency medicine or remote clinical settings. Its reduced leadset and portable design facilitate efficient and diagnostic-quality ECG recordings outside of a specialized cath lab environment.

View Impala →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature FFRangio System Impala
Pricing Contact vendor for pricing information. Contact for pricing
Deployment SaaS, on-prem, hybrid Portable device, integrated with mobile applications/platforms.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Impala

Tool B (Impala) offers a significant usability advantage with its reduced leadset for 12-lead ECG acquisition, simplifying a traditionally complex and time-consuming procedure. This makes advanced cardiac assessment more accessible and faster for a wider range of healthcare professionals in various settings.

Clinical Value

FFRangio System

Tool A (FFRangio System) provides wire-free and drug-free 3D FFR guidance, which is a substantial advancement in interventional cardiology. This innovation directly enhances the safety and precision of PCI decision-making, optimizing treatment strategies and reducing risks associated with traditional invasive methods.

Pricing & Value

Tie

Both tools require direct contact for pricing information, making it impossible to assess their relative pricing transparency or value proposition. Without specific cost details or comparative economic studies, a definitive winner cannot be determined.

Enterprise Readiness

FFRangio System

Tool A (FFRangio System) demonstrates stronger enterprise readiness through its on-premise deployment and seamless integration with existing cath lab equipment and PACS. Furthermore, its ISO 27001 certification indicates a robust commitment to information security, crucial for large healthcare organizations.

Innovation

FFRangio System

Tool A (FFRangio System) presents a more disruptive innovation with its wire-free and drug-free 3D FFR guidance, fundamentally changing how physiological assessments are performed during PCI. This represents a significant paradigm shift in a complex interventional procedure.

Support & Docs

Tie

The provided information for both Tool A and Tool B lacks specific details regarding their support services or available documentation. Without this crucial information, it is not possible to differentiate between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature FFRangio System Impala
Name FFRangio System Impala
Company CathWorks AliveCor
Primary Function Wire-free and drug-free 3D FFR guidance for optimizing PCI decisions in coronary artery disease. Portable, AI-powered 12-Lead ECG device for healthcare professionals.
Core Measurement/Analysis Real-time FFRangio values at every point on the coronary tree, simulated pullback curve, lesion impact assessment. 12-Lead ECG acquisition, detects life-threatening cardiac conditions including heart attacks.
Technology/Methodology Artificial intelligence aids in quick angiogram analysis, eliminates invasive pressure wires, drugs, or guide catheters. AI technology (KAIu2122 12L) for cardiac determinations, reduced leadset for easier placement.
Target Specialties Cardiology Cardiology, Emergency Medicine

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and Impala.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize PCI decisions for patients with coronary artery disease. Impala is a portable, AI-powered 12-Lead ECG device designed for rapid cardiac assessment and detection of life-threatening cardiac conditions, including heart attacks.
The FFRangio System uses AI for quick angiogram analysis and to provide real-time FFRangio values and insights for PCI optimization. Impala leverages its KAIu2122 12L AI technology to generate 12-Lead ECG recordings and make cardiac determinations, including the detection of life-threatening conditions.
The FFRangio System eliminates the need for invasive pressure wires, drugs, or a guide catheter for FFR measurement, making that aspect of coronary physiology assessment less invasive. Impala is a completely non-invasive, portable device that acquires ECGs with a reduced leadset for easier and rapid placement.
AliveCor's Impala explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA). While the FFRangio System handles protected health information (PHI) and is ISO 27001 certified for information security, its HIPAA compliance is unknown and a BAA is likely but not explicitly stated on its public website.
The FFRangio System is primarily categorized under Cardiology AI and Surgical AI, specifically for cardiologists involved in interventional procedures. Impala is designed for Cardiology and Emergency Medicine, offering rapid cardiac assessment for healthcare professionals in various settings.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring FFRangio System or Impala

Backers

Who funded each tool's parent company.

Impala

AI Tool Finder
AI-powered search. Results may not be comprehensive.